The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.

The prevalence of drug-resistant infections is expected to propel the growth of the antibiotic-resistance market going forward. Drug-resistant infections are diseases caused by resistant bacteria, resulting in an infection that is far more difficult or impossible to cure.

• Antimicrobial resistance drugs help treat various drug-resistant infections with improved antibiotic treatment outcomes concerning both target and nontarget pathogens.
• According to the European Centre for Disease Prevention and Control, around 35,000 persons in the EU/EEA die each year from antimicrobial-resistant diseases.
• Infections such as Klebsiella pneumoniae and Candida auris cases are on the rise, indicating the pressing need for effective treatments.
• The prevalence of drug resistance infection is driving the antibiotic resistance market.

Read More On The Antibiotic Resistance Market Report 2024 – https://www.thebusinessresearchcompany.com/report/antibiotic-resistance-global-market-report

Product Innovations In The Antibiotic Resistance Market

Product innovations are the key trend gaining popularity in the antibiotic resistance market.

• Major companies are focused on developing innovative products to strengthen their position in the market.
• Alkem Laboratories Limited introduced Zidavi, a novel antibiotic for multi-drug resistant (MDR) infections, in January 2023.
• Zidavi offers an effective alternative to treat hospital-acquired pneumonia (HAP) and severe intra-abdominal infections (IAIs) caused by meropenem and colistin.
• Innoviva Inc. acquired Entasis Therapeutics Holdings Inc in July 2022 to strengthen its antibacterial portfolio.

Market Segmentation

The antibiotic resistance market covered in this report is segmented into several categories:

1. By Drug Class: Beta Lactum Antibiotic, Cephalosporins, Quinolones Antibiotics, Macrolide Antibiotics, Tetracyclines, Oxazolidinones, Other Drug Classes.
2. By Pathogen: Staphylococcus aureus, Staphylococcus pneumonia, Neisseria gonorrhoeae, Enterococcus Faecium, Escherichia coli, Klebsiella pneumonia, Shigella, Clostridium difficile, Other pathogens.
3. By Disease Type: Urinary tract infection, Intra-abdominal infection, Bloodstream infections, Clostridium difficile infections, Other Disease Types.
4. By Mechanism of Action: Protein Synthesis Inhibitors, Cell Wall Synthesis Inhibitors, RNA Synthesis Inhibitors, DNA Synthesis Inhibitors, Other Mechanism Of Actions.
5. By End Users: Hospitals, Homecare, Specialty clinics, Other End-users.

Regional Insights

• North America was the largest region in the antibiotic resistance market in 2023.
• Asia-Pacific is expected to be the fastest-growing region in the forecast period.

Conclusion

The antibiotic resistance market is witnessing robust growth, driven by the rising prevalence of drug-resistant infections and advancements in product innovations. As major companies continue to focus on developing novel treatments and expanding their portfolios, the market is poised for further expansion. With increased awareness and collaborative efforts, stakeholders aim to address the challenges posed by antimicrobial resistance effectively, ensuring better treatment outcomes and public health worldwide.

Request for A Sample Of The Global Antibiotic Resistance Market Report:
https://www.thebusinessresearchcompany.com/sample_request?id=12131&type=smp